Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1982;13(Suppl 2):149S–158S. doi: 10.1111/j.1365-2125.1982.tb01904.x

Pindolol--the pharmacology of a partial agonist.

B J Clark, K Menninger, A Bertholet
PMCID: PMC1402130  PMID: 7049208

Abstract

1 Pindolol is a non-selective beta-adrenoceptor blocking agent; its affinity to adrenoceptors in guinea pig atria (beta 1) is not significantly different from that in guinea pig trachea (beta 1 + beta 2) and canine vascular smooth muscle (beta 2). 2 Pindolol displays a striking diversity of agonist activities in isolated tissues. Stimulant effects correspond to 40--50% of the maximum effects of isoprenaline in isolated kitten atria and guinea pig trachea and to only 10% in guinea pig atria. Effects in canine isolated mesenteric vessels are those of a full agonist, maximum responses equaling those of isoprenaline. These findings suggest that the stimulant effects of pindolol are exerted principally on beta 2-adrenoceptors. 3 Cardiac stimulation produced by pindolol in the dog is sufficient to compensate for the cardiac depression resulting from blockade of beta-adrenoceptors in the heart. Reductions in cardiac output and compensatory increases in total peripheral resistance do not occur or are much smaller than those produced by beta-adrenoceptor blocking agents lacking sympathomimetic activity. 4 Pindolol-induced relaxation of bronchial smooth muscle prevents or minimizes the bronchoconstrictor effects of injected spasmogens in the cat. 5 Pindolol has marked vasodilator activity, small doses reducing femoral and mesenteric vascular resistance by approximately 30%. Doses comparable to those used in hypertensive patients lower blood pressure by 20 mmHg in non-anaesthetized dogs.

Full text

PDF
149S

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Atterhög J. H., Dunér H., Pernow B. Experience with pindolol, a betareceptor blocker, in the treatment of hypertension. Am J Med. 1976 May 31;60(6):872–876. doi: 10.1016/0002-9343(76)90907-4. [DOI] [PubMed] [Google Scholar]
  2. Barrett A. M., Carter J. Comparative chronotropic activity of beta-adrenoceptive antagonists. Br J Pharmacol. 1970 Nov;40(3):373–381. doi: 10.1111/j.1476-5381.1970.tb10619.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bertholet A., Milavec M., Waite R. A study of beta-adrenoceptors in the guinea pig. Postgrad Med J. 1981;57 (Suppl 1):9–17. [PubMed] [Google Scholar]
  4. Bilski A., Robertson H. H., Wale J. L. A study of the relationship between cardiac beta-adrenoceptor blockade and intrinsic sympathomimetic activity in rats depleted of catecholamines. Clin Exp Pharmacol Physiol. 1979 Jan-Feb;6(1):1–9. doi: 10.1111/j.1440-1681.1979.tb00001.x. [DOI] [PubMed] [Google Scholar]
  5. Hedberg A., Minneman K. P., Molinoff P. B. Differential distribution of beta-1 and beta-2 adrenergic receptors in cat and guinea-pig heart. J Pharmacol Exp Ther. 1980 Mar;212(3):503–508. [PubMed] [Google Scholar]
  6. Lang E., Holtmann W. Veränderungen der Hämodynamik unter dem Einfluss der beta-Sympathikolyse bei zwei verschiedenen Substanzen unterschiedlichen pharmakodynamischen Prinzips. Arzneimittelforschung. 1974 Sep;24(9):1330–1335. [PubMed] [Google Scholar]
  7. Man in 't Veld A. J., Schalekamp M. A. Pindolol acts as beta-adrenoceptor agonist in orthostatic hypotension: therapeutic implications. Br Med J (Clin Res Ed) 1981 Mar 21;282(6268):929–931. doi: 10.1136/bmj.282.6268.929. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Minneman K. P., Pittman R. N., Molinoff P. B. Beta-adrenergic receptor subtypes: properties, distribution, and regulation. Annu Rev Neurosci. 1981;4:419–461. doi: 10.1146/annurev.ne.04.030181.002223. [DOI] [PubMed] [Google Scholar]
  9. O'Donnell S. R., Wanstall J. C. pA2 values of selective beta-adrenoceptor antagonists on isolated atria demonstrate a species difference in the beta-adrenoceptor populations mediating chronotropic responses in cat and guinea-pig. J Pharm Pharmacol. 1979 Oct;31(10):686–690. doi: 10.1111/j.2042-7158.1979.tb13629.x. [DOI] [PubMed] [Google Scholar]
  10. Rosenthal J., Kaiser H., Raschig A., Welzel D. Treatment of hypertension with a beta-adrenoceptor blocker. A multicentre trial with pindolol. Br J Clin Pract. 1979 Jun;33(6):165-74, 181. [PubMed] [Google Scholar]
  11. Simpson W. T. Nature and incidence of unwanted effects with atenolol. Postgrad Med J. 1977;53 (Suppl 3):162–167. [PubMed] [Google Scholar]
  12. Svendsen T. L., Hartling O., Trap-Jensen J. Immediate haemodynamic effects of propranolol, practolol, pindolol, atenolol and ICI 89,406 in healthy volunteers. Eur J Clin Pharmacol. 1979 May 21;15(4):223–228. doi: 10.1007/BF00618509. [DOI] [PubMed] [Google Scholar]
  13. Tsukiyama H., Otsuka K., Miyamoto K., Hashimoto M., Yasutake S. Hemodynamic effects of beta-adrenergic blockade with pindolol, oxprenolol, propranolol and bufetolol hydrochloride in essential hypertension. Jpn Circ J. 1976 Jun;40(6):655–664. doi: 10.1253/jcj.40.655. [DOI] [PubMed] [Google Scholar]
  14. Waite R. Activité sympathomimétique intrinsèque des bêta-bloquants. Nouv Presse Med. 1978 Sep 20;7(31):2707–2709. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES